ARTICLE | Company News
Bancel letter showcases Moderna’s focus on mRNA vaccines
January 6, 2020 11:30 PM UTC
Updated on Jan 6, 2020 at 11:51 PM UTC
Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses.
With 21 candidates spanning six treatment paradigms and more than a dozen disease indications, Moderna’s pipeline breadth has been widely viewed as a key differentiating factor (see “Moderna’s Land Grab”). ...
BCIQ Company Profiles